Randomized controlled clinical trial to evaluate the efficacy of Eladi churna in the management of urdhwag amlapitta with special reference to GERD
Abstract
Amlapitta is one of the most common diseases seen in society. The word Amlapitta is made up of Amla and Pitta. Aacharya Kashyapa was the first person who described Amlapitta as a separate disease. Madhav Nidan, Bhavprakash, and Yogratnakara have also described it very well.The disease in which the sour quality of Pitta dosha aggravates and changes to extreme acidic sourness is called Amlapitta. Amlapitta is Annavaha Strotas Vyadhi (gastrointestinal disease), which is caused due to Agnimandya and vitiations of Pachaka Pitta. Urdhwag Amlapitta can be correlated with GERD. Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal diseases. It is defined on the basis of both esophageal and extra-esophageal symptoms and/or lesions resulting from the reflux of gastric contents into the esophagus. The sign and symptoms of Urdhwag Amlapitta (GERD) are Avipak (Indigestion), Klama (Tiredness), Utklesha (Nausea), Tikta amla udgar (Sour and bitter Belching), Gaurvata (Heaviness), Hruth Kantha Daha (Heart and Throat Burning), and Aruchi (Anorexia).In the present era, consumption of fast food, junk food, anxiety, and depression are the main causes of Amlapitta.In this clinical study, Eladi churna was used, which is described by Yogratnakar in Amlapitta chikitsa .A total of 70 patients were taken, which were divided into two groups of 35 patients for each group. Group A-Eladi Churna ( Trial)and Group B- Amlapittapinashak yog as a control drug mentioned in…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 70 participants or records.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.